# EXCALIBER-RRMM (NCT04975997)

> Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

A report exists for this trial.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04975997
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Celgene
- Conditions: Multiple Myeloma
- Interventions: Dexamethasone; Daratumumab; Bortezomib; Iberdomide; Iberdomide; Iberdomide; Dexamethasone; Daratumumab
- Enrollment: 939
- Primary outcome: Progression-free Survival (PFS)
- Primary outcome: Minimal Residual Disease (MRD) negative Complete Response (CR) at any time

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

None in our index yet.